Ser265

Site Information
EQLARQGsFRGFPAL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 456490

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 ) , mutation of modification site ( 1 )
Disease tissue studied:	breast cancer ( 1 )
Relevant cell line - cell type - tissue:	Jurkat (T lymphocyte) ( 2 ) , MCF-7 (breast cell) ( 1 ) , MDCKII (epithelial) ( 1 )

Upstream Regulation
Putative in vivo kinases:	PKCZ (human) ( 1 )

Downstream Regulation
Effects of modification on NUMB iso3:	intracellular localization ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:	endocytosis, inhibited ( 1 )
Inhibit interaction with:	AP2A1 (human) ( 1 ) , CDH1 (human) ( 1 ) , CTNND1 (human) ( 1 )

References
1	Sato K, et al. (2011) Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Mol Biol Cell 22, 3103-3119 21775625 Curated Info
2	Zhou J (2009) CST Curation Set: 5898; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info

References

Sato K, et al. (2011) Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Mol Biol Cell 22, 3103-3119
21775625 Curated Info

Zhou J (2009) CST Curation Set: 5898; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info